| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P41-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-443
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-44 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-616
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P41-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-443
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate |
2008-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2010-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2010522169-A |
| titleOfInvention |
Reduction of adverse events after percutaneous intervention through the use of thrombin receptor antagonists |
| abstract |
Preventing adverse clinical events in patients undergoing percutaneous coronary or peripheral percutaneous interventional treatment comprising administering to the patient a therapeutically effective amount of a thrombin receptor antagonist such as SCH530348 A method is disclosed. Administering a loading dose of SCH 530348 of about 40 mg between 1 hour before and short of the treatment can cause a therapeutically effective level of platelet aggregation. In some embodiments, the adverse clinical event is myocardial infarction, emergency revascularization, or ischemia requiring hospitalization. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11678659-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019206543-A |
| priorityDate |
2007-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |